Nxt-ID, Inc. (NXTD) Reaches $1.93 Formed H&S; Last Week BioLineRx Ltd. (BLRX) Coverage

BioLineRx Ltd. (NASDAQ:BLRX) Logo

Among 6 analysts covering BioLineRx (NASDAQ:BLRX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioLineRx had 26 analyst reports since July 27, 2015 according to SRatingsIntel. H.C. Wainwright maintained BioLineRx Ltd. (NASDAQ:BLRX) on Tuesday, September 26 with “Buy” rating. The firm has “Buy” rating by Maxim Group given on Thursday, May 18. H.C. Wainwright maintained BioLineRx Ltd. (NASDAQ:BLRX) on Friday, June 2 with “Buy” rating. The rating was maintained by TH Capital on Monday, July 27 with “Buy”. Maxim Group maintained it with “Buy” rating and $300 target in Thursday, June 1 report. The stock has “Buy” rating by Maxim Group on Monday, July 10. H.C. Wainwright maintained the shares of BLRX in report on Friday, May 26 with “Buy” rating. Maxim Group downgraded the stock to “Hold” rating in Friday, August 12 report. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, August 9. H.C. Wainwright maintained BioLineRx Ltd. (NASDAQ:BLRX) on Wednesday, January 17 with “Buy” rating. See BioLineRx Ltd. (NASDAQ:BLRX) latest ratings:

20/03/2018 Broker: Oppenheimer Rating: Buy Maintain
06/03/2018 Broker: Oppenheimer Rating: Buy New Target: $3.0 Maintain
06/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain
17/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain
21/12/2017 Broker: Oppenheimer Rating: Buy New Target: $3.0 Initiate
21/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain
04/12/2017 Broker: Oppenheimer Rating: Buy New Target: $3.0 Maintain
04/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain
21/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain

Nxt-ID, Inc. (NXTD) formed H&S with $1.81 target or 6.00% below today’s $1.93 share price. Nxt-ID, Inc. (NXTD) has $46.99 million valuation. The stock decreased 2.53% or $0.05 during the last trading session, reaching $1.93. About 287,668 shares traded. Nxt-ID, Inc. (NASDAQ:NXTD) has risen 6.18% since May 4, 2017 and is uptrending. It has underperformed by 5.37% the S&P500.

The stock decreased 3.61% or $0.03 during the last trading session, reaching $0.8. About 214,663 shares traded. BioLineRx Ltd. (NASDAQ:BLRX) has declined 24.35% since May 4, 2017 and is downtrending. It has underperformed by 35.90% the S&P500.

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company has market cap of $83.20 million. The Company’s development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. It currently has negative earnings. The companyÂ’s other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome.

BioLineRx Ltd. (NASDAQ:BLRX) Ratings Chart